Sumitomo Pharma Co., Ltd.: Rhinitis, Allergic trials

The registry lists 13 Rhinitis, Allergic studies with Sumitomo Pharma Co., Ltd. as lead sponsor. 0 are open to participants now and 12 have results posted.

Phase 1 2Phase 3 10Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)CompletedNCT01654536Phase 4Results posted
• A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)CompletedNCT01458275Phase 3Results posted
• A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).CompletedNCT01451541Phase 3Results posted
• Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal SprayCompletedNCT01401465Phase 3Results posted
• Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic RhinitisCompletedNCT01378429Phase 3Results posted
• A Phase 1 Scintigraphy Study to Assess Nasal Deposition of Ciclesonide. Using a Novel Nasal Metered Dose InhalerCompletedNCT01371786Phase 1Results posted
• Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic RhinitisCompletedNCT01287364Phase 3Results posted
• A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and OlderCompletedNCT01067105Phase 3Results posted
• Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) AxisCompletedNCT01033825Phase 3Results posted
• Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and OlderCompletedNCT01010971Phase 3Results posted
• A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and OlderCompletedNCT00953147Phase 3Results posted
• Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic RhinitisCompletedNCT00790023Phase 3Results posted
• DSP-3025 Study of Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of SeasonCompletedNCT00925678Phase 1